Nxera Pharma Co (TYO:4565) partner Neurocrine Biosciences has initiated a Phase 3 trial for NBI-1117568, an oral muscarinic M4 receptor agonist, for treating schizophrenia, according to a Thursday filing on the Tokyo Stock Exchange.
The trial follows positive Phase 2 results reported in August 2024, showing a significant reduction in symptoms.
The global, placebo-controlled trial will enroll around 280 patients with acute schizophrenia symptoms. The primary endpoint is the reduction of PANSS score, with secondary endpoints focusing on clinical severity.
No milestone payment is due at trial start, but a $15 million payment will be triggered when the first patient is dosed.
Price (JPY): $934.00, Change: $+18, Percent Change: +1.97%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。